Thalidomide and thalidomide analogs reduce HIV type 1 replication in human macrophages in Vitro

AIDS Research and Human Retroviruses

Volumn 13, Issue 10, 1997, Pages 857-863

  Moreira, André L ^a   Corral, Laura G ^b   Ye, Weiguo ^a   Johnson, Barbara ^a   Stirling, David ^b   Muller, George W ^b   Freedman, Victoria H ^a   Kaplan, Gilla ^a  

^a ROCKEFELLER UNIVERSITY   (United States)

^b CELGENE CORPORATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MESSENGER RNA; RNA DIRECTED DNA POLYMERASE; THALIDOMIDE; THALIDOMIDE DERIVATIVE; TUMOR NECROSIS FACTOR ALPHA; VIRUS RNA;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MACROPHAGE; MONONUCLEAR CELL; NORTHERN BLOTTING; PRIORITY JOURNAL; VIRUS REPLICATION;

EID: 0031005338     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1997.13.857     Document Type: Article

References (43)

1. Mellors JW, Rinaldo CR, Gupta P, White RM, Todd JA, and Kingsley LA: Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996;272:1167-1170.
2. Klausner JD, Makonkawwkeyoon S, Akarasewi P, Nakata K, Kasinrerk W, Corral LG, Dewar RL, Clifford-Lane H, Freedman VH, and Kaplan G: The effect of thalidomide on the pathogenesis of human immunodeficiency virus type 1 and M. tuberculosis infection. J AIDS and Hum Retroviruses 1996;11:247-257.
3. Wallis RS, Vjecha M, Amir-Tahmasseb M, Okwera A, Byekwaso F, Nyole S, Kabengera S, Mugerwa RD, and Ellner JJ: Influence of tuberculosis on human immunodeficiency virus: Enhanced cytokine expression and elevated β2-microglobulin in HIV-1 associated tuberculosis. J Infect Dis 1993;167:43-48.
4. Whalen C, Horsburg CR Jr, Hom D, Labart C, Simberkoff S, and Ellner JJ: Accelerated clinical course of HIV-1 infection following active tuberculosis. Clin Res 1993;41:290A.
5. Pape JW, Jean SS, Ho JL, Hafner A, and Johnson WD Jr: Effect of isoniazid prophylaxis on the incidence of active tuberculosis and progression of HIV infection. Lancet 1993;342:268-272.
6. Matsuyma T, Kobayashi N, and Yamamoto N: Cytokines and HIV infection: Is AIDS a tumor necrosis factor disease? AIDS 1991;5:1405-1417.
7. Zangerle R, Gallati H, Sarcletti M, Wachter H, and Fuchs D: Tumor necrosis factor alpha and soluble tumor necrosis factor receptors in individuals with human immunodeficiency virus infection. Immunol Lett 1994;41:229-234.
8. Chollet-Martin S, Simon F, Matheron S, Joseph CA, Elbim C, and Gougerot-Pocidalo MA: Comparison of plasma cytokine levels in African patients with HIV-1 and HIV-2 infection. AIDS 1994;8: 879-884.
9. Brown CC, Poli G, Lubaki N, St. Louis M, Davachi F, Musey L, Manzila T, Kovacs A, Quinn TC, and Fauci AS: Elevated levels of tumor necrosis factor-alpha in Zairian neonates plasmas: Implications for perinatal infection with the human immunodeficiency virus. J Infect Dis 1994;169:975-980.
10. Ayehunie S, Sonnerborg A, Yemane-Berhan T, Zewdie DW, Britton S, and Strannegard O: Raised levels of tumor necrosis factor-alpha and neopterin, but not interferon-alpha, in serum of HIV-1-infected patients from Ethiopia. Clin Exp Immunol 1993;91:37-42.
11. Sinicco A, Biglino A, Sciandra M, Forno B, Pollono AM, Raiteri R, and Gioannini P: Cytokine network and acute primary HIV-1 infection. AIDS 1993;7:1167-1172.
12. Ciardi M, Sharief MK, Thompson EJ, Salotti A, Vullo V, Sorice F, and Cirelli A: High cerebrospinal fluid and serum levels of tumor necrosis factor-alpha in asymptomatic HIV-1 seropositive individuals. Correlation with interleukin-2 and soluble IL-2 receptor. J Neurol Sci 1994;125:175-179.
13. Bilello JA, Stellricht K, Drusano GL, and Stein DS: Soluble tumor necrosis factor-α receptor II (sTNF-α RII) correlates with human immunodeficiency virus (HIV) RNA copy numbers in HIV-infected patients. J Infect Dis 1996;173:464-467.
14. Folks TM, Justement J, Kinter A, Schnittman S, Orenstein J, Poli G, and Fauci AS: Characterization of a promonocyte clone chronically infected with HIV-1 and inducible by 13-phorbol-12-myristate acetate. J Immunol 1988;140:1117-1122.
15. Poli G and Fauci AS: Cytokine modulation of HIV-1 expression. Semin Immunol 1993;5:165-173.
16. Osborn L, Kunkel S, and Nabel GJ: Tumor necrosis factor α and interleukin 1 stimulate the human immunodeficiency virus enhancer by activation of the nuclear factor κB. Proc Natl Acad Sci USA 1989;86:2336-2340.
17. Pomerantz RS, Feinberg MB, Trono D, and Baltimore D: Lipopolysaccharide is a potent monocyte/macrophage specific stimulator of human immunodeficiency virus type 1 expression. J Exp Med 1990;172:253-261.
18. Bachelerie F, Alcami J, Arenzana-Seisdedos F, and Virelizier JL: HIV enhancer activity perpetuated by NF-κB induction of infection of monocytes. Nature (London) 1991;350:709-712.
19. Bauerle PA and Henkel T: Function and activation of NF-κB in the immune system. Annu Rev Immunol 1994;12:141-179.
20. Sampaio EP, Sarno EN, Gallily R, Cohn ZA, and Kaplan G: Thalidomide selectively inhibits tumor necrosis factor α production by stimulated human monocytes. J Exp Med 1991;173: 699-703.
21. Moreira AL, Sampaio EP, Zmuidzinas A, Fridt P, Smith KA, and Kaplan G: Thalidomide exerts its inhibitory action on tumor necrosis factor-α by enhancing mRNA degradation. J Exp Med 1993;177:1675-1680.
22. Sampaio EP, Kaplan G, Miranda A, Nery JAC, Miguel CP, Viana SM, and Sarno EN: The influence of thalidomide on the clinical and immunological manifestation of erythema nodosum leprosum. J Infect Dis 1993;168:408-414.
23. Makonkawkeyoon S, Limson-Pobre RNR, Moreira A, Schauf V, and Kaplan G: Thalidomide inhibits the replication of human immunodeficiency virus type 1. Proc Natl Acad Sci USA 1993;90: 5974-5978.
24. Kaplan G and Moreira AL: TNFα regulation of HIV-1: Biology and therapy. Res Immunol 1994;145:685-689.
25. Corral LG, Muller GW, Moreira AL, Chen Y. Wu M, Stirling D, and Kaplan G: Selection of novel analogs of thalidomide with enhanced tumor necrosis factor α inhibitory activity. Mol Med 1996;2:506-515.
26. Perno CF, Yarchoan R, Cooney DA, Hartman NR, Webb DSA, Hao Z, Mitsuya H, Johns DG, and Broder S: Replication of human immunodeficiency virus in monocytes. J Exp Med 1989;169: 933-951.
27. Leonard J, Parrot C, Buckler-White AJ, Turner W, Ross EK, Martin MA, and Rabson AB: The NF-κB binding sites in the human immunodeficiency virus type 1 long terminal repeat are not required for virus infectivity. J Virol 1989;63:4919-4924.
28. Muller GW, Corral LG, Shire MG, Wang H, Moreira A, Kaplan G, and Stirling DI: Structural modifications of thalidomide produce analogs with enhanced tumor necrosis factor inhibitory activity. J Med Chem 1996;39:3238-3240.
29. Zwingenberger K and Wnendt S: Immunomodulation by thalidomide: Systemic review of the literature and of unpublished observations. J Inflamm 1996;46:177-211.
30. Granelli-Piperno A and Nolan P: Nuclear transcription factors that bind to elements of the IL-2 promoter. Induction requirements in primary human T cells. J Immunol 1991;147:2734-2739.
31. Westendorp MO, Shatrov VA, Schulze-Osthoff K, Frank R, Kraft M, Los M, Krammer PH, Droge W, and Lehmann V: HIV-1 Tat potentiates TNF-induced NF-kappa B activation and cytotoxicity by altering the cellular redox state. EMBO J 1995;14:546-554.
32. Zauli G, Furlini G, Re MC, Milani D, Capitani S, and La Placa M: Human immunodeficiency virus type 1 (HIV-1) Tat-protein stimulates the production of interleukin-6 (IL-6) by peripheral blood monocytes. Microbiologica 1993;16:115-120.
33. Papp B, Zhang D, Groopman JE, and Byrn RA: Stimulation of human immunodeficiency virus type 1 expression by ceramide. AIDS Res Hum Retroviruses 1994;10:775-780.
34. Muller JM, Ziegler-Heitbrock HW, and Bauerle PA: Nuclear factor kappa B, a mediator of lipopolysaccharide effects. Immunobiology 1993;187:233-256.
35. Luznik L, Kraus G, Guatelli J, Richman D, and Wong-Staal F: Tat-independent replication of human immunodeficiency viruses. J Clin Invest 1995;95:328-332.
36. Popik W and Pitha PM: Role of tumor necrosis factor alpha in activation and replication of the tat-defective human immunodeficiency virus type-1. J Virol 1993;67:1094-1099.
37. Popik W and Pitha PM: Differential effect of tumor necrosis factor-alpha and herpes simplex virus type-1 on the Tat-target inhibition of human immunodeficiency virus type-1 replication. Virology 1994;202:521-529.
38. Quian J, Bours V, Manischewitz J, Blackburn R, Siebenlist U, and Golding H: Chemically selected sub clones of CEM cell line demonstrate resistance to HIV-1 infection resulting from the selective loss of NF-κB DNA binding proteins. J Immunol 1994;152: 4183-4191.
39. Jacque JM, Fernandez B, Arenzana-Seisdedos F, Thomas D, Baleux F, Virelizier JL, and Bacherlerie F: Permanent occupancy of the human immunodeficiency virus type 1 enhancer by NF-κB is needed for persistent viral replication in monocytes. J Virol 1996;70:2930-2938.
40. Paterson DL, Georghiou PR, Allworth AM, and Kemp RJ: Thalidomide as treatment of refractory aphtous ulceration related to human immunodeficiency virus infection. Clin Infect Dis 1995;20: 250-254.
41. Tramontana JM, Utaipat U, Molloy A, Akarasewi P, Burroughs M, Klausner JD, Rom W, and Kaplan G: Thalidomide treatment reduces tumor necrosis factor a production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995;1:384-397.
42. Gardner-Medwin JMM, Smith NJ, and Powell RJ: Clinical experience with thalidomide in the management of severe oral and genital ulceration in conditions such as Behçet's disease: Use of neurophysiological studies to detect thalidomide neuropathy. Ann Rheum Dis 1994;53:828-832.
43. Williams I, Weller IVD, Malin A, Anderson J, and Waters MFR: Thalidomide hypersensitivity in AIDS. Lancet 1991;337:436-437.